# Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer

> **NCT00002659** · PHASE3 · UNKNOWN · sponsor: **Matrix Pharmaceutical** · enrollment: 120 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** cisplatin-e therapeutic implant

## Key facts

- **NCT ID:** NCT00002659
- **Lead sponsor:** Matrix Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1995-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2013-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002659, "Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00002659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*